PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRivastigmine
Exelon(rivastigmine)
Exelon, Nimvastid, Prometax, Rivastigmine (rivastigmine) is a small molecule pharmaceutical. Rivastigmine was first approved as Exelon on 1998-05-11. It is used to treat alzheimer disease in the USA. It has been approved in Europe to treat alzheimer disease, dementia, and parkinson disease. The pharmaceutical is active against cholinesterase and acetylcholinesterase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Exelon, Rivastigmine (discontinued: Exelon, Rivastigmine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rivastigmine tartrate
Tradename
Company
Number
Date
Products
EXELONNovartisN-020823 DISCN2000-04-21
4 products, RLD
EXELONNovartisN-021025 DISCN2000-04-21
1 products, RLD
Hide discontinued
Rivastigmine
Tradename
Company
Number
Date
Products
EXELONSandozN-022083 RX2007-07-06
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
exelonNew Drug Application2024-05-08
rivastigmineANDA2024-09-21
rivastigmine tartrateANDA2024-10-24
rivastigmine transdermal systemANDA2025-01-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
alzheimer diseaseEFO_0000249D000544F03
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06D: Anti-dementia drugs
— N06DA: Anticholinesterase anti-dementia drugs
— N06DA03: Rivastigmine
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
MalnutritionD044342EFO_0008572E40-E461————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRivastigmine
INNrivastigmine
Description
Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a neuroprotective agent and a cholinergic drug. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+).
Classification
Small molecule
Drug classcholinesterase inhibitors (physostigmine type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
Identifiers
PDB—
CAS-ID123441-03-2
RxCUI—
ChEMBL IDCHEMBL636
ChEBI ID8874
PubChem CID77991
DrugBankDB00989
UNII IDPKI06M3IW0 (ChemIDplus, GSRS)
Target
Agency Approved
BCHE
BCHE
ACHE
ACHE
Organism
Homo sapiens
Gene name
BCHE
Gene synonyms
CHE1
NCBI Gene ID
Protein name
cholinesterase
Protein synonyms
Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, cholinesterase (serum) 2, cholinesterase 1, Pseudocholinesterase
Uniprot ID
Mouse ortholog
Bche (12038)
cholinesterase (Q543J3)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Exelon – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rivastigmine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,932 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18,407 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use